Table 1 Baseline clinical and pathological characteristics of patients using ypTNM stage or pTNM stage in Peking University Cancer Hospital & Institute, 2007–2015 (n = 1441)
Characteristics | Total (N = 1441) | ypTNM (N = 449) | pTNM (N = 992) | P value* |
|---|---|---|---|---|
Age (μ ± sd) | 59.2 ± 11.4 | 59.3 ± 10.2 | 59.1 ± 11.9 | 0.69 |
Female | 397 (27.55%) | 102 (22.72%) | 295 (29.74%) | 0.006 |
Family history of cancer (yes) | 328 (22.76%) | 81 (18.04%) | 247 (24.9%) | 0.004 |
BMI (μ ± sd, kg/m2) | 23.5 ± 3.4 | 23.4 ± 3.3 | 23.5 ± 3.5 | 0.71 |
ECOG | 0.08 | |||
0 | 928 (64.4%) | 290 (64.59%) | 638 (64.31%) | |
1 | 419 (29.08%) | 139 (30.96%) | 280 (28.23%) | |
2 | 94 (6.52%) | 20 (4.45%) | 74 (7.46%) | |
Tumor location | < 0.001 | |||
Upper | 393 (27.27%) | 166 (36.97%) | 227 (22.88%) | |
Middle | 212 (14.71%) | 59 (13.14%) | 153 (15.42%) | |
Low | 784 (54.41%) | 195 (43.43%) | 589 (59.38%) | |
Whole | 52 (3.61%) | 29 (6.46%) | 23 (2.32%) | |
Short diameter (μ ± sd, in cm) | 2.9 ± 2.1 | 3.1 ± 2.4 | 2.9 ± 2.0 | 0.21 |
Long diameter (μ ± sd, in cm) | 4.2 ± 2.8 | 4.5 ± 3.1 | 4.0 ± 2.6 | 0.035 |
Pathological type | < 0.001 | |||
Adenocarcinoma | 1089 (75.57%) | 356 (79.29%) | 733 (73.89%) | |
Signet ring cell carcinomaa | 290 (20.12%) | 67 (14.92%) | 223 (22.48%) | |
Mucinous adenocarcinomab | 62 (4.3%) | 26 (5.79%) | 36 (3.63%) | |
Differentiation grade | 0.029 | |||
Well | 159 (11.03%) | 36 (8.02%) | 123 (12.4%) | |
Moderate | 666 (46.22%) | 206 (45.88%) | 460 (46.37%) | |
Poor | 616 (42.75%) | 207 (46.1%) | 409 (41.23%) | |
T stage | < 0.001 | |||
T1 | 296 (20.54%) | 35 (7.8%) | 261 (26.31%) | |
T2 | 238 (16.52%) | 68 (15.14%) | 170 (17.14%) | |
T3 | 216 (14.99%) | 66 (14.7%) | 150 (15.12%) | |
T4 | 691 (47.95%) | 280 (62.36%) | 411 (41.43%) | |
N stage | 0.002 | |||
N0 | 606 (42.05%) | 157 (34.97%) | 449 (45.26%) | |
N1 | 249 (17.28%) | 94 (20.94%) | 155 (15.63%) | |
N2 | 234 (16.24%) | 84 (18.71%) | 150 (15.12%) | |
N3a | 224 (15.54%) | 67 (14.92%) | 157 (15.83%) | |
N3b | 128 (8.88%) | 47 (10.47%) | 81 (8.17%) | |
TNM stage | < 0.001 | |||
IA | 261 (18.11%) | 25 (5.57%) | 236 (23.79%) | |
IB | 159 (11.03%) | 43 (9.58%) | 116 (11.69%) | |
IIA | 110 (7.63%) | 30 (6.68%) | 80 (8.06%) | |
IIB | 227 (15.75%) | 102 (22.72%) | 125 (12.6%) | |
IIIA | 185 (12.84%) | 76 (16.93%) | 109 (10.99%) | |
IIIB | 237 (16.45%) | 85 (18.93%) | 152 (15.32%) | |
IIIC | 262 (18.18%) | 88 (19.6%) | 174 (17.54%) | |
Vascular cancer embolus (yes) | 876 (60.79%) | 291 (64.81%) | 585 (58.97%) | 0.035 |
Hospital stay (μ ± sd, in days) | 14.2 ± 13.8 | 14.6 ± 16.8 | 13.9 ± 11.9 | 0.11 |
Operative time (μ ± sd, in min) | 206.2 ± 64.4 | 212.1 ± 63.6 | 203.6 ± 64.7 | 0.003 |
Blood loss (μ ± sd, in ml) | 150.6 ± 210.7 | 175.2 ± 324.6 | 139.5 ± 128.4 | < 0.001 |
Gastrectomy type | < 0.001 | |||
Laparoscopicc | 186 (12.91%) | 24 (5.35%) | 162 (16.33%) | |
Open | 1255 (87.09%) | 425 (94.65%) | 830 (83.67%) | |
Resection range | < 0.001 | |||
Total | 496 (34.42%) | 210 (46.77%) | 286 (28.83%) | |
Distal | 785 (54.48%) | 171 (38.08%) | 614 (61.9%) | |
Proximal | 141 (9.78%) | 55 (12.25%) | 86 (8.67%) | |
Thoraticabdominal joint | 19 (1.32%) | 13 (2.9%) | 6 (0.6%) | |
Multi-organ excision (yes) | 80 (5.55%) | 36 (8.02%) | 44 (4.44%) | 0.006 |
Reconstruction approach | < 0.001 | |||
Billroth II | 342 (23.73%) | 77 (17.15%) | 265 (26.71%) | |
Billroth I | 412 (28.59%) | 88 (19.6%) | 324 (32.66%) | |
Roux-en-Y | 369 (25.61%) | 138 (30.73%) | 231 (23.29%) | |
Jejunal interposition | 165 (11.45%) | 83 (18.49%) | 82 (8.27%) | |
Other | 153 (10.62%) | 63 (14.03%) | 90 (9.07%) | |
ASA | 0.21 | |||
1 | 205 (14.23%) | 60 (13.36%) | 145 (14.62%) | |
2 | 969 (67.24%) | 316 (70.38%) | 653 (65.83%) | |
3 | 267 (18.53%) | 73 (16.26%) | 194 (19.56%) | |
N of lymph nodes dissected (μ ± sd) | 31.0 ± 12.0 | 32.0 ± 12.2 | 30.5 ± 11.9 | 0.06 |
N of lymph nodes metastasis (μ ± sd) | 4.7 ± 7.5 | 5.2 ± 8.0 | 4.4 ± 7.2 | 0.004 |